![]() ![]() Third-quarter 20 adjusted EBITDA includes $19.0 million and $4.0 million, respectively, in acquired IPR&D and milestones expenses. These achievements reflect our commitment to bring innovative medicines to more patients in need." "We advanced our pipeline, achieving several important R&D milestones, including completing enrollment in our TEPEZZA trial for chronic/low CAS thyroid eye disease and announcing positive Phase 2 topline results from our dazodalibep trial in Sjögren’s syndrome. "Our third-quarter focus on clinical, commercial and operational execution drove continued progress across our portfolio," said Tim Walbert, chairman, president and chief executive officer, Horizon. First Patient Enrolled in ADX-914 Phase 2 Trial in Collaboration with Q32 Bio -ĭUBLIN, November 02, 2022-( BUSINESS WIRE)-Horizon Therapeutics plc (Nasdaq: HZNP) today announced third-quarter 2022 financial results and increased its full-year 2022 net sales and adjusted EBITDA guidance. Announced Positive Topline Data from Phase 2 Dazodalibep Sjögren’s Syndrome Trial Planning to Initiate a Phase 3 Clinical Program in 2023. Completed Enrollment in TEPEZZA Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) Trial Topline Results Expected in the Second Quarter of 2023. Peak Annual Net Sales Expectations to Greater than $1.5 Billion. Peak Annual Net Sales Expectations to Greater than $1 Billion, Bringing Global Peak Annual Net Sales Expectations to Greater than $4 Billion. Increasing Full-Year 2022 KRYSTEXXA Net Sales Growth Expectations to Approximately 25%. Continue to Expect Full-Year 2022 TEPEZZA Net Sales Percentage Growth in the High Teens. Increasing Full-Year 2022 Adjusted EBITDA Guidance to $1.32 Billion to $1.34 Billion, Which Includes $52.5 Million of Acquired IPR&D and Milestones Expenses. ![]() Increasing Full-Year 2022 Net Sales Guidance to $3.59 Billion to $3.61 Billion. 30, 2022 -įull-Year 2022 Guidance and Peak Annual Net Sales Expectations: ![]() Cash Position of $2.13 Billion as of Sept. KRYSTEXXA ® (pegloticase injection) Net Sales of $191.6 Million. TEPEZZA ® (teprotumumab-trbw) Net Sales of $490.9 Million. GAAP Net Income of $135.8 Million Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones Expenses. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |